drugset / Trial / NCT04756323
A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)
Phase 2
Unknown
1000 enrolled
Beijing Minhai Biotechnology Co., Ltd
Jiangsu Province Centers for Disease Control and Prevention · collabShenzhen Kangtai Biological Products Co., LTD · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This study is a randomized, double-blinded, and placebo controlled phase Ⅱ clinical trial of the SARS-CoV-2 inactivated vaccine to evaluate the safety and immunogenicity of the experimental vaccine in healthy adults ⩾18 years.
Timeline
- Start
- 2020-10-27
- Primary completion
- 2021-06-30
- Completion
- 2022-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | inactivated SARS-CoV-2 vaccine | Vaccine | — | — |